Pyroptosis inducer-1
Pyroptosis inducer-1 is a pyroptosis inducer. Pyroptosis inducer-1 promotes STING phosphorylation, NF-κB activation, caspase-1-dependent pyroptosis, GSDMD cleavage, mitochondrial membrane potential disruption, ROS production, S phase cell cycle arrest, ER stress, calcium release, and immunogenic cell death accompanied by CRT exposure, HMGB1 release, and ATP secretion. Pyroptosis inducer-1 enters cancer cells via endocytosis and accumulates in mitochondria and endoplasmic reticulum. Pyroptosis inducer-1 increases dendritic cells and CD8+ T cells while decreasing regulatory T cells. Pyroptosis inducer-1 can be used for breast cancer research.
For research use only. We do not sell to patients.
- CAS No.: 3081319-75-4
- Formula: C54H46ClF8N8O2PRu
- Molecular Weight:1158.48
-
Storage:
Please store the product under the recommended conditions in the Certificate of Analysis.
All Caspase Isoforms
More
Biological Activity
Description
Cellular Effect
|
Cell Line
|
Type | Value | Description | References |
|---|---|---|---|---|
| MCF7 | IC50 |
1.43 μM
|
Antiproliferative activity against human breast cancer MCF-7 cells assessed as reduction in cell viability incubated for 48 hrs.
Antiproliferative activity against human breast cancer MCF-7 cells assessed as reduction in cell viability incubated for 48 hrs.
|
42570373 |
| 143B | IC50 |
1.36 μM
|
Antiproliferative activity against human osteosarcoma 143B cells assessed as reduction in cell viability incubated for 48 hrs.
Antiproliferative activity against human osteosarcoma 143B cells assessed as reduction in cell viability incubated for 48 hrs.
|
42570373 |
| Caco-2 | IC50 |
3.40 μM
|
Antiproliferative activity against human colorectal cancer Caco-2 cells assessed as reduction in cell viability incubated for 48 hrs.
Antiproliferative activity against human colorectal cancer Caco-2 cells assessed as reduction in cell viability incubated for 48 hrs.
|
42570373 |
| HeLa | IC50 |
1.27 μM
|
Antiproliferative activity against human cervical cancer HeLa cells assessed as reduction in cell viability incubated for 48 hrs.
Antiproliferative activity against human cervical cancer HeLa cells assessed as reduction in cell viability incubated for 48 hrs.
|
42570373 |
| HepG2 | IC50 |
1.75 μM
|
Antiproliferative activity against human hepatocellular carcinoma HepG2 cells assessed as reduction in cell viability incubated for 48 hrs.
Antiproliferative activity against human hepatocellular carcinoma HepG2 cells assessed as reduction in cell viability incubated for 48 hrs.
|
42570373 |
| MCF-10A | IC50 |
4.72 μM
|
Antiproliferative activity against non-tumorigenic human mammary epithelial MCF-10A cells assessed as reduction in cell viability incubated for 48 hrs.
Antiproliferative activity against non-tumorigenic human mammary epithelial MCF-10A cells assessed as reduction in cell viability incubated for 48 hrs.
|
42570373 |
In Vitro
Pyroptosis inducer-1 (Ru3) (48 h) exhibits potent broad-spectrum antiproliferative activity against human cancer cell lines, including MCF-7, with IC50 values ranging from 1.27 to 3.40 μM[1].
Pyroptosis inducer-1 (2 μM; 30 min-4 h) rapidly enters MCF-7 cells via an endocytosis-associated pathway and preferentially accumulates in the mitochondria and endoplasmic reticulum[1].
Pyroptosis inducer-1 (2-6 μM; 8 h) induces significant mitochondrial membrane depolarization and dysfunction in MCF-7 cells[1].
Pyroptosis inducer-1 (2-6 μM) effectively induces the release of multiple DAMPs (CRT exposure, HMGB1 release, ATP secretion) in MCF-7 cells, thereby triggering ICD-related responses[1].
Pyroptosis inducer-1 (2-6 μM) effectively activates the cGAS-STING signaling pathway in MCF-7 cells, potentially exerting antitumor immunomodulatory effects[1].
Pyroptosis inducer-1 (2-6 μM) induces pronounced intracellular oxidative stress through massive ROS accumulation in MCF-7 cells[1].
Pyroptosis inducer-1 (2-6 μM; 24 h) disrupts normal cell cycle progression and inhibits the proliferative capacity of MCF-7 cells through induction of S-phase arrest[1].
Pyroptosis inducer-1 (2-6 μM; 8-24 h) triggers caspase-1-dependent pyroptosis in MCF-7 cells, characterized by morphological changes and release of pro-inflammatory cytokines[1].
Pyroptosis inducer-1 (2-6 μM; 6 h) effectively induces ER stress in MCF-7 cells, characterized by calcium release and activation of the eIF2α-ATF4-Chop signaling axis[1].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only. Further protocols information, click here.
-
Cell Line:MCF-7
-
Concentration:2 μM
-
Incubation Time:30 min; 4 h; 1 h
-
Result:Intracellular red fluorescence was detectable after 30 min, with intense distribution in the cytoplasm after 4 h.
Colocalized significantly with mitochondrial (PCC = 0.68) and ER (PCC = 0.73) probes, but showed limited overlap with lysosomal probe (PCC = 0.49).
-
Cell Line:MCF-7
-
Concentration:2 μM; 4 μM; 6 μM
-
Incubation Time:24 h
-
Result:Markedly induced S-phase arrest.
The proportion of cells in the S phase increased from 25.8% in the control group to 41.1% following treatment with 6 μM Ru3.
The percentage of cells in the G2/M phase decreased from 26.3% to 16.2%.
-
Cell Line:MCF-7
-
Concentration:2 μM; 4 μM; 6 μM
-
Incubation Time:8 h; 24 h
-
Result:Treated cells exhibited typical pyroptotic morphological features including cellular swelling, membrane disruption, and bubble-like protrusions.
ELISA showed significantly elevated extracellular levels of IL-6, TNF-α, and IFN-β.
NSA pretreatment attenuated Ru3-induced cytotoxicity.
Western blot demonstrated concentration-dependent upregulation of Cleaved-Caspase-1 and increased GSDMD-N expression.
-
Cell Line:MCF-7
-
Concentration:2 μM; 4 μM; 6 μM
-
Incubation Time:6 h
-
Result:Increased the fluorescence intensity of Fluo-3 (HY-126821) in a concentration-dependent manner.
In Vivo
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
-
Animal Model:BALB/c (female)[1]
-
Dosage:6 μM
-
Administration:s.c.; single dose
-
Result:Inhibited tumor growth with a tumor growth inhibition rate of 80.21% on day 16 and 86.69% on day 30.
Increased the proportion of CD11c+ dendritic cells in the spleen by approximately 2.5-fold.
Increased the number of CD4+ T cells in the spleen and tumors by approximately 5.9-fold and 3.6-fold, respectively.
Increased the proportion of CD8+ T cells in the spleen and tumors by approximately 5.9-fold and 3.2-fold, respectively.
Reduced the proportion of regulatory T cells (Tregs) in the spleen and tumors, which were approximately 3.4-fold and 6.2-fold higher in control mice, respectively.
Chemical Information
-
CAS No. 3081319-75-4
-
Molecular Weight 1158.48
-
Formula C54H46ClF8N8O2PRu
-
SMILES
O=C(COCCN1CCN(C(C2=CC=C(C=C2)Cl)C3=CC=CC=C3)CC1)NC4=CC5=CC=C[N]6=C5C7=[N]([Ru+2]689([N]%10=C(C%11=[N]9C=CC=C%11)C=CC=C%10)[C-]%12=C(C%13=[N]8C=CC=C%13)C(F)=CC(F)=C%12)C=CC=C74.[F-][P+5]([F-])([F-])([F-])([F-])[F-]
-
Shipping
Room temperature in continental US; may vary elsewhere.
-
Storage
Please store the product under the recommended conditions in the Certificate of Analysis.
Protocols
-
Western Blot
Western blotting (WB) is a commonly used experimental method in molecular biology, biochemistry, and immunogenetics for identifying and quantifying target proteins. It combines gel electrophoresis with immunoassay, enabling researchers to analyze protein expression, post-translational modifications, and molecular weight.
-
Mitochondrial membrane-potential fluorescent assay
Mitochondrial membrane potential fluorescent assays estimate ΔΨm in living cells using lipophilic cationic dyes such as TMRM, TMRE, rhodamine 123, and JC-1, which accumulate in mitochondria according to membrane polarization; loss of signal after FCCP or CCCP treatment is interpreted as mitochondrial depolarization. TMRM/TMRE and rhodamine 123 are commonly used for semi-quantitative live-cell microscopy or flow cytometry, while JC-1 can report a shift from red aggregate fluorescence to green monomer fluorescence during depolarization; interpretation requires controls because dye concentration, quenching mode, cell type, dye efflux, and mitochondrial mass can affect fluorescence independently of ΔΨm.
-
Mammalian live/dead viability and cytotoxicity staining
Live/dead viability and cytotoxicity staining assays are based on the simultaneous detection of intracellular esterase activity in metabolically active (viable) cells and membrane integrity loss in non-viable cells. In commonly used dual-staining approaches, membrane-permeant fluorogenic substrates are converted by intracellular esterases into fluorescent products in live cells, while impermeant DNA-binding dyes selectively enter cells with compromised plasma membranes and label nucleic acids in dead or dying cells, enabling discrimination between viable and non-viable populations by fluorescence microscopy or flow cytometry.
-
ROS/oxidative-stress fluorescent staining
ROS/oxidative-stress fluorescent staining uses cell-permeant fluorogenic probes that become fluorescent after oxidation inside cells or tissues; commonly used examples include DCFH-DA/DCFDA for broad cellular oxidant detection, DHE for superoxide-related signal detection, MitoSOX for mitochondrial superoxide-related signal detection, and CellROX probes for oxidative-stress-associated fluorescence readouts. The assay detects probe oxidation rather than a single ROS species unless the probe and analysis method have been chemically validated for that species. DCFH-DA enters cells, is deacetylated by intracellular esterases to DCFH, and produces fluorescent DCF after oxidation, so the readout is used as an operational measure of total cellular oxidative stress rather than a species-specific ROS measurement. DHE and MitoSOX can report superoxide-related oxidation, but red fluorescence alone can include non-specific ethidium-like oxidation products; HPLC or optimized spectral approaches are
-
BrdU Incorporation Assay
Bromodeoxyuridine (BrdU) incorporation assay is based on the principle that BrdU, a thymidine analog, is incorporated into newly synthesized DNA during the S phase of the cell cycle, thereby serving as a marker of DNA replication and cellular proliferation. Incorporated BrdU can be detected using anti-BrdU antibodies following DNA denaturation, enabling visualization or quantification of proliferating cells through immunochemical detection methods such as immunofluorescence or immunohistochemistry.
-
Protocol for Cell Cycle
Cell-cycle analysis by flow cytometry measures DNA content in single cells to estimate the fraction of cells in G0/G1, S, and G2/M phases. Propidium iodide intercalates into DNA, and after RNA removal with RNase, fluorescence intensity reflects cellular DNA content: 2N cells are assigned to G0/G1, cells between 2N and 4N to S phase, and 4N cells to G2/M. DNA-content analysis alone cannot reliably separate G0 from G1 or G2 from M. Ki-67 can distinguish quiescent G0 cells from cycling cells, EdU or BrdU incorporation marks active DNA synthesis in S phase, and phospho-histone H3 staining identifies mitotic cells within the 4N population.
-
Research Protocol for Inflammation-related Diseases
The NLRP3 inflammasome is a cytosolic innate immune signaling platform that integrates priming signals and danger-signal activation to promote caspase-1 activation, maturation of IL-1β and IL-18, and gasdermin D-mediated pyroptotic cell death. The core experimental logic is to determine whether inflammatory disease phenotypes are driven by increased NLRP3 expression, ASC-containing inflammasome assembly, caspase-1 cleavage, GSDMD cleavage, and extracellular release of IL-1β/IL-18 rather than by nonspecific cell injury alone. The pathway is strongly linked to inflammation-related disease phenotypes because monosodium urate crystals activate NALP3/NLRP3 inflammasome signaling in gout-like crystal inflammation, cholesterol crystals activate NLRP3 inflammasomes in atherogenesis models, and DSS-induced intestinal inflammation has been reported to involve NLRP3 inflammasome activity. However, experimental colitis studies also show context-dependent protective effects of NLRP3 inflammasome co
-
Breast Cancer Modeling
Breast cancer is a heterogeneous cancer, and it has been distinguished into four subtypes: luminal A, luminal B, HER2-positive and basal-like. Molecular mutations, epigenetic alterations, hormone exposure and immune microenvironment are related to the progression of breast cancer.
-
Kinase activity and phosphorylation assays
Kinase activity assays measure the ability of kinases to transfer phosphate groups from ATP to specific substrates, while phosphorylation assays detect the presence and levels of phosphorylated proteins. Common methods include radiolabeled ATP incorporation (e. g. ,), ADP release detection via bioluminescence (e. g. ,[3]), enzyme-linked immunosorbent assays (ELISA) for phospho-specific epitopes (e. g. ,[6]), and microtiter-based formats for high-throughput screening (e. g. ,[8]). The ADP-Glo assay quantifies kinase activity by measuring ADP produced during phosphorylation using a luciferase-based system. Radiometric assays involve autoradiography or scintillation counting after incorporation of 32P-labeled ATP into substrate proteins. ELISA-based approaches rely on phospho-specific antibodies to detect activated kinases in cell lysates or purified samples.
-
EdU Incorporation Assay (Click Chemistry-Based DNA Synthesis Measurement)
The EdU incorporation assay measures DNA synthesis by adding the thymidine analog 5-ethynyl-2′-deoxyuridine to cells or tissues, where it is incorporated into newly synthesized DNA during S phase. Incorporated EdU is detected by copper-catalyzed azide-alkyne cycloaddition, in which a fluorescent azide covalently reacts with the ethynyl group on EdU, allowing S-phase cells to be detected by fluorescence microscopy, flow cytometry, or high-content imaging. EdU detection does not require DNA denaturation or anti-BrdU antibody access, which preserves sample structure and improves compatibility with immunostaining and multiparameter cytometry compared with BrdU-based detection. EdU can be cytotoxic in a cell-type- and exposure-dependent manner, so pulse duration, concentration, and continuous-labeling designs should be validated for each cell type.
-
Flow cytometric DNA-content cell-cycle staining
Flow cytometric DNA-content cell-cycle staining measures the fluorescence intensity of DNA-bound fluorochromes in single cells or nuclei to estimate DNA content distributions, allowing assignment of populations to G0/G1, S, and G2/M phases by DNA histogram deconvolution. Propidium iodide (PI) intercalates into DNA, and PI fluorescence is proportional to cellular DNA content when staining is performed under conditions that make DNA accessible and minimize non-DNA signal. Cells with G2/M DNA content are expected to show approximately twice the fluorescence intensity of G0/G1 cells, while S-phase cells occupy intermediate fluorescence values. PI-based DNA-content analysis can also detect cells with fractional DNA content, often reported as sub-G1, when DNA fragmentation and extraction during staining reduce retained DNA signal in apoptotic cells. DAPI is an alternative DNA fluorochrome for univariate DNA-content analysis, while bivariate approaches combining DNA content with proliferation
-
Cell Cytotoxicity Assay
Cytotoxicity assays are usually based on the assessment of cell membrane damage, which can also be indirectly detected by measuring cell viability. Detection methods include MTT assay, CKK-8 assay, LDH assay and ATP assay, etc.
-
Fluorescent plasma-membrane potential dye assay
Fluorescent plasma-membrane potential dye assays measure changes in cell membrane potential using voltage-sensitive dyes whose fluorescence changes when cells depolarize or hyperpolarize. Anionic bis-oxonol dyes such as DiBAC4(3) enter depolarized cells more readily and show increased fluorescence after intracellular binding, while hyperpolarization reduces dye accumulation and fluorescence. FMP/FLIPR membrane-potential dyes are used for faster, homogeneous microplate assays of ion-channel or receptor-mediated membrane-potential changes.
-
Mitochondrial membrane-potential and mitochondrial mass staining
Mitochondrial membrane potential staining measures the electrochemical polarization across the mitochondrial inner membrane in live cells using lipophilic cationic fluorescent probes; early rhodamine-based work showed that selective mitochondrial dye accumulation is lost when the mitochondrial transmembrane potential is dissipated. JC-1 reports mitochondrial polarization by shifting from green monomer fluorescence to red J-aggregate fluorescence as dye concentration increases within energized mitochondria; therefore, the red/green fluorescence ratio is used as a relative readout of mitochondrial membrane potential. TMRE or TMRM staining provides a single-channel relative readout because these cationic rhodamine esters accumulate in polarized mitochondria, and lower fluorescence indicates reduced mitochondrial polarization when acquisition and dye-loading conditions are controlled. Mitochondrial mass staining is commonly performed with MitoTracker Green FM or related MitoTracker dyes as
-
Apoptosis Solutions
Apoptosis is a regulated, generally non-lytic cell-death pathway that removes unwanted, damaged, infected, or abnormal cells through coordinated morphological changes, caspase activation, DNA fragmentation, and membrane remodeling. The intrinsic apoptosis pathway is controlled mainly by mitochondrial outer membrane permeabilization, BCL-2 family proteins, cytochrome c release, apoptosome formation, caspase-9 activation, and downstream executioner caspase-3/7 activation. The extrinsic apoptosis pathway is initiated by death receptors such as Fas, TNFR, and TRAIL receptors, which recruit adaptor proteins and activate caspase-8 before engaging executioner caspases or mitochondrial amplification through BID cleavage. Apoptosis is linked to many phenotypes, including cancer cell killing, tissue homeostasis, immune regulation, neurodegeneration, infection response, and treatment-induced cytotoxicity; unresolved questions include how apoptosis interacts with necroptosis, pyroptosis, ferroptos
-
Calcium Spark Assay
Calcium sparks are localized, transient increases in intracellular calcium concentration ([Ca2+]i) that occur in cardiac myocytes and represent elementary events underlying excitation-contraction coupling. These events are generated by the coordinated opening of clusters of ryanodine receptors (RyRs) on the sarcoplasmic reticulum membrane, leading to a brief release of Ca2+ into the cytosol. The detection and analysis of calcium sparks provide insights into the mechanisms of calcium handling and signaling in cardiac cells. Imaging techniques using fluorescent calcium indicators such as Fluo-3 are employed to visualize these subcellular calcium transients with high spatial and temporal resolution. The protocol is based on established methodologies described in primary literature for both experimental measurement and automated analysis of calcium sparks.
-
Protocol for Kinase activity and phosphorylation assays
Kinase activity assays measure transfer of phosphate from ATP to a protein or peptide substrate, generating phosphorylated substrate, ADP, or incorporated radiolabeled phosphate as the readout; phosphorylation assays measure site-specific phosphorylation in cells or tissues as a proxy for kinase-pathway activation, inhibition, or substrate regulation. Phosphorylation can be detected by phospho-specific Western blot, immunoprecipitation kinase assay, phospho-immunofluorescence, phospho-flow cytometry, luminescent ADP detection, radiolabeled ATP incorporation, or reporter-based pathway assays, and these readouts can be applied to cancer cells, primary neurons, mouse tumors, organoids, inflammatory macrophages, ferroptosis studies, and mitophagy studies when the kinase target is biologically relevant.
-
Monocyte-derived dendritic cell differentiation
Human monocyte-derived dendritic cells are generated by isolating PBMC-derived monocytes and culturing them with GM-CSF plus IL-4, which produces cells with dendritic-cell antigen-presenting properties, reduced monocyte phenotype, and increased dendritic-cell functional readouts such as antigen uptake, allogeneic T-cell stimulation, and expression of markers including HLA-DR, CD80, CD86, CD83, CD1a, or CD209 depending on protocol and maturation state. The main readout is phenotypic and functional differentiation: immature MoDCs are commonly evaluated by loss or reduction of CD14 with acquisition of dendritic-cell markers and antigen uptake capacity, whereas mature MoDCs are evaluated by increased CD83, CD80, CD86, HLA-DR, and T-cell stimulatory function after exposure to maturation stimuli such as TNF-α or a cytokine/PGE2 cocktail.
-
Pyroptosis Solutions
Pyroptosis is a lytic inflammatory cell-death pathway executed by gasdermin pores, most classically through inflammasome-mediated activation of caspase-1, cleavage of gasdermin D, membrane pore formation, LDH release, and secretion of IL-1β and IL-18. The canonical pathway is commonly modeled by priming cells with an inflammatory signal such as LPS to induce pro-IL-1β and inflammasome components, followed by an activation signal such as ATP or nigericin to activate NLRP3, ASC speck formation, caspase-1 cleavage, GSDMD cleavage, cytokine release, and pyroptotic membrane rupture. The non-canonical pathway is triggered when cytosolic LPS activates mouse caspase-11 or human caspase-4/5, leading to GSDMD cleavage and pyroptosis, and this can secondarily activate NLRP3-dependent IL-1β release. Pyroptosis is linked to inflammatory injury, infection, cancer, liver disease, ocular disease, placental inflammation, and other disease phenotypes, but unresolved questions include which gasdermin fam
Purity & Documentation
References
Calculators
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
Keywords
- Pyroptosis inducer-1
- 3081319-75-4
- Pyroptosis inducer1
- Pyroptosis inducer 1
- Pyroptosis
- STING
- NF-κB
- Caspase
- Reactive Oxygen Species (ROS)
- GSDMD cleavage
- mitochondrial membrane potential disruption
- S-phase cell cycle arrest
- cGAS-STING pathway
- STING phosphorylation
- pyroptosis
- ER stress
- caspase-1-dependent pyroptosis
- ROS generation
- NF-κB activation
- Inhibitor
- inhibitor
- inhibit